Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Singapore Med J. 2019 May;60(5):236-240. doi: 10.11622/smedj.2018150. Epub 2018 Nov 29.
Intravenous (IV) thrombolysis with alteplase (rt-PA) is effective in ischaemic stroke. The primary objective was to evaluate predictors of functional outcome in acute ischaemic stroke (AIS) patients treated with IV rt-PA. The secondary objective was to assess the outcome with the modified Rankin scale (mRS). We also examined the predictive value of the Totaled Health Risks in Vascular Events (THRIVE) score.
AIS patients treated with IV rt-PA from February 2012 to August 2016 were recruited. Demographic data, National Institutes of Health Stroke Scale (NIHSS) scores, timing and neuroradiological findings were recorded. Patients received a dose of 0.9 mg/kg IV rt-PA within 4.5 hours of symptom onset. mRS score was evaluated at discharge and three months, and good and poor clinical outcomes were defined as scores of 0-2 and 3-6, respectively. Baseline THRIVE scores were assessed.
36 patients received IV rt-PA. 20 (55.6%) patients had an mRS score of 0-2 at three months. Based on THRIVE score, 86.1% had a good or moderately good prognosis. On univariate analysis, poor outcome was associated with NIHSS score before rt-PA (p = 0.03), THRIVE score (p = 0.02), stroke subtype (p = 0.049) and diabetes mellitus (DM; p = 0.06). Multiple logistic regression showed that outcome was significantly associated with NIHSS score before rt-PA (p = 0.032) and DM (p = 0.010).
Our newly developed Malaysian IV rt-PA service is safe, with similar outcomes to the published literature. Functional outcome after thrombolysis was associated with baseline NIHSS score and DM.
阿替普酶(rt-PA)静脉溶栓治疗对缺血性脑卒中有效。主要目的是评估接受静脉 rt-PA 治疗的急性缺血性脑卒中(AIS)患者的功能结局预测因素。次要目标是评估改良 Rankin 量表(mRS)的结果。我们还检查了 Totaled Health Risks in Vascular Events(THRIVE)评分的预测价值。
纳入 2012 年 2 月至 2016 年 8 月接受静脉 rt-PA 治疗的 AIS 患者。记录人口统计学数据、国立卫生研究院卒中量表(NIHSS)评分、时间和神经影像学发现。患者在症状出现后 4.5 小时内接受 0.9 mg/kg 静脉 rt-PA 治疗。在出院和三个月时评估 mRS 评分,良好和不良临床结局定义为评分 0-2 和 3-6。评估基线 THRIVE 评分。
36 例患者接受静脉 rt-PA 治疗。20 例(55.6%)患者在三个月时 mRS 评分 0-2。根据 THRIVE 评分,86.1%的患者预后良好或中度良好。在单变量分析中,溶栓前 NIHSS 评分(p = 0.03)、THRIVE 评分(p = 0.02)、卒中亚型(p = 0.049)和糖尿病(DM;p = 0.06)与不良结局相关。多变量逻辑回归显示,结局与溶栓前 NIHSS 评分(p = 0.032)和 DM(p = 0.010)显著相关。
我们新开发的马来西亚静脉 rt-PA 服务是安全的,与已发表的文献结果相似。溶栓后功能结局与基线 NIHSS 评分和 DM 相关。